Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722564 · ClinicalTrials.gov registry record · NA
Accuracy of Self-estimation of Blood Alcohol Concentration Compared to Object Values
A NA study, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT02722564: Completed NA study, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
NCT02722564 is a NA study that has completed, run by St. Luke's Hospital and Health Network, Pennsylvania. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02722564, a NA study, has completed, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
This will be a prospective survey study. The participants will all be volunteers of legal drinking age. Each participant will consume one alcoholic beverage (beer) at a time and then will be asked to verbally estimate their current blood alcohol concentration and if the subject feels they are able to drive. At that time, their BAC level will be measured objectively using a breath alcohol test (BAT) device. The participant will not be told their objective value. This will continue with a verbal estimate and actual BAT reading after every drink until the participant reaches a minimum BAC of 0.10. At this time, participants will continue to be monitored until their BAC falls to 0.08 and they are clinically sober. As their blood alcohol level decreases, the investigators will ask the participant to estimate their level every hour along with an actual reading until reaching 0.08. Statistical analyses will be used to determine how accurate self estimation is in regards to blood alcohol content.
Primary Outcome
The change was measured both when participants' breath alcohol content was ascending to 0.1 and descending to 0.08.
Interventions
- BEHAVIORAL self estimation of breath alcohol content
- DEVICE breath alcohol content as measured by Alco Sensor IV device
- OTHER drink a beer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02722564 record still lists
NCT02722564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which self estimation of breath alcohol content is the first listed.
NCT02722564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02722564 about?
NCT02722564 is a clinical study titled "Accuracy of Self-estimation of Blood Alcohol Concentration Compared to Object Values". This will be a prospective survey study. The participants will all be volunteers of legal drinking age. Each participant will consume one alcoholic beverage (beer) at a time and then will be asked to verbally estimate their current blood alcohol concentration and if the subject feels they are able t...
What is the current status of trial NCT02722564?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2015-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02722564?
The interventions under investigation include: self estimation of breath alcohol content (BEHAVIORAL), breath alcohol content as measured by Alco Sensor IV device (DEVICE), drink a beer (OTHER).
Who is sponsoring clinical trial NCT02722564?
This trial is sponsored by St. Luke's Hospital and Health Network, Pennsylvania, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02722564's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia